• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Accuray closes $277 million TomoTherapy merger

Accuray closes $277 million TomoTherapy merger

June 13, 2011 By MassDevice staff

Accuray_100_0.jpg

Accuray Inc. (NSDQ:ARAY) completed its $277 million acquisition of TomoTherapy Inc. (NSDQ:TOMO), tying the bow on a deal first announced in March 2010.

The closing roughly doubles Accuray’s footprint in the radiation oncology market. The Sunnyvale, Calif.-based radiosurgery device maker is significantly smaller than its new acquisition, with 200 fewer employees than TomoTherapy’s 636. But Accuray’s 2010 revenues were about 6 percent higher than TomoTherapy’s, at $206 million compared to $195 million. And Accuray’s finances are in much better shape: ARAY was profitable in 2010, posting just under $7 million in net income, compared to a $30 million net loss for TomoTherapy.

Accuray will immediately recoup more than half of the purchase price by assuming TomoTherapy’s cash reserves, to boot. As of Dec. 31, 2010, TOMO had $270 million in assets, including $152 million in cash and equivalents and $163 million in shareholder equity.

“The successful closing of this transaction is a significant accomplishment and an important milestone in Accuray’s history. Scale is important in the capital equipment industry, and today Accuray’s installed base more than doubles, generating greater opportunity for service revenue and for replacement business over time to customers who have purchased these best-in-class technologies,” Accuray CEO Euan Thomson said in a prepared release. “We appreciate the support of our investors and the contributions of our stakeholders who helped us achieve this important transaction. We look forward to working toward achieving our goals as a stronger, unified company.”

The deal increases Accuray’s installed base from 226 systems to more than 550 in 32 countries; its total headcount will be more than 1,000 worldwide. Company officials said they will maintain a “significant presence” in Madison, Wis., where TomoTherapy’s home base.

Shares of TomoTherapy common stock will stop trading on NASDAQ before the market opens June 13.

Filed Under: Mergers & Acquisitions, News Well, Oncology, Radiosurgery/Radiation therapy, Wall Street Beat Tagged With: Accuray Inc., TomoTherapy Inc.

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy